Investors
Due to a significant new commercial opportunity, Occuity is delighted to give existing shareholders and our community of friends and followers, some of whom may have missed out in the first rounds, the opportunity to invest in our business and join us on our journey.
The new opportunity identified in the ophthalmic market will allow Occuity to build on the significant progress made on its patented handheld technology platform. By combining technical elements from both the PM1 Pachymeter and the GM1 Glucose meter, to create a non-contacting, handheld, device that will measure the 'Axial Length' of the human eye in just a few seconds. Already working in prototype form, the finished AX1 Axiometer device will revolutionise the key measurement required for myopia management in children – probably the fastest growing market in the global Ophthalmology/Optometry sector today.
Investor Information
What Type of Investor Are You?
Experienced Investors - High Net Worth Individuals (HNWI) / Sophisticated & Professional.
Occuity is open to discussing investment from a range of investors. If you are able to self-certify as either an investment professional, HNWI or sophisticated investor and would like to know more, then please complete the form to request our Investment Memorandum.
Please note the minimum direct investment we are able to accept is £10,000
Crowdfunding - Seedrs
In 2021, Occuity became the largest MedTech fundraising round ever on Seedrs.
Since then, significant progress has been made and Occuity was delighted to once again be able to offer retail investors, friends, family and supporters the opportunity to invest in Occuity, become equity shareholders and join us on our journey to improve the lives of hundreds of millions of people. The 2022 campaign ended in overfunding with 533 investors raising over £1.6 million, surpassing our expectations by a significant margin.
Self Certify as HNW/Sophisticated Investor
& Sign NDA
Thank you for your interest in Occuity. To enable us to send you further information such as the Investor Memorandum, please complete the form below. If you are not yet registered, you will need to self-certify and then sign an NDA, due to the confidential nature of our detailed memorandum.
About Occuity
We're revolutionising the way in which some of the world’s most prevalent chronic diseases are screened and monitored. Our devices work by harmlessly shining a low power beam of light into the eye, collecting and analysing the return signal and are unlike anything else currently on the market.
We have developed a novel, globally patented (9 granted, 5 pending, 1 in process) non-contacting technology that is able to accurately detect changes in the eye and thereby derive information not only about a patient’s ocular health but also about their broader wellbeing, particularly where this relates to chronic, life-changing conditions.
Occuity is developing its disruptive technology into a range of handheld devices aimed at some of the major health problems of our time. Due to the size of the market, we are particularly interested in addressing diabetes by both developing products that will enable earlier diagnosis of the condition and will also enable non-contacting, pain-free glucose monitoring.
Our first product using the patented technology will be the Occuity PM1 pachymeter, a handheld device for opticians to optically measure the thickness of the cornea to support glaucoma diagnosis. The prototype is at the point of undergoing clinical trials, is due to be ready for sale in 2023. A new opportunity has also been identified in the ophthalmic market.
The new opportunity identified in the ophthalmic market will allow Occuity to build on the significant progress made on its patented handheld technology platform. By combining technical elements from both the PM1 Pachymeter and the GM1 Glucose meter, to create a handheld, non-contacting device that will measure the 'Axial Length' of the human eye in just a few seconds. Already working in prototype form, the finished AX1 Axiometer device will revolutionise the key measurement required for myopia management in children – probably the fastest growing market in the global Ophthalmology/Optometry sector today.
Following on from this will be more advanced meters to screen first for diabetes, then for Alzheimer’s Disease and then a personal blood glucose meter for use by people with diabetes. Our products will address markets collectively worth around $35Bn pa.
